21 Jul Empowering Tomorrow’s Patients: 2022 PPI insights paper released
Following the success of the Patient Partnership Index 2022, OVID Health is proud to release our insights paper which brings together the key lessons and advice from this year’s top partnerships, as well as the expert insight of senior leaders in pharma and patient advocacy, following our virtual event in July.
Our paper, Empowering Tomorrow’s Patients, explores how pharma companies and patient groups can build meaningful and long-lasting partnerships which deliver real impact to address deep-rooted challenges.
The Patient Partnership Index, now in its third year, is a first-of-its-kind initiative from OVID Health, designed to set the benchmark for what makes a successful partnership between pharma and patient groups. Entries are awarded GOLD, SILVER or FINALIST standard by the expert judging panel for the Index, which this year included Sarah Woolnough (CEO, Asthma + Lung UK), Collette Goldrick (Executive Director Strategy and Partnerships, ABPI), John James (CEO, Sickle Cell Society) and Jenny Ousbey (CEO, OVID Health).
To help share best practice and raise the standard for patients, we’ve made our insights paper free and easy to access online. You can read and download the Patient Partnership Index 2022 insights paper, Empowering Tomorrow’s Patients here.
You can also rewatch our PPI event to hear directly from this year’s judges and some of the GOLD awarded entrants.
If you have any questions, comments, or think OVID Health can help with your next patient advocacy project, contact us at [email protected] to arrange a discussion.
Patient Partnership Index 2022
GOLD Standard
Galapagos Biotech
Gilead Sciences
Gilead Sciences Ltd UK and Ireland
Medicine Discovery Catapult (MDC)
Novo Nordisk
Roche
Sanofi
SILVER Standard
Eli Lilly and Company
Gilead Sciences Ltd UK and Ireland
GSK
Janssen
LEO Pharma
Novo Nordisk
Pfizer
Vifor Pharma
FINALIST Standard
Novo Nordisk
Pfizer
Takeda